Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.76 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GUSB | P08236 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112913 | 0.84 | GAA (0.74) | ALDH1A1GAAHTTMAPTRAB9A | |
| SCHEMBL4669190 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GAACA1CA2ALOX12 | |
| SCHEMBL10113522 | 0.81 | ALDH1A1 (0.61) | ALDH1A1GAACA1CA2ALOX12 | |
| SCHEMBL13419868 | 0.77 | GAA (0.70) | ALDH1A1GAACA1CA2HTT | |
| SCHEMBL26671671 | 0.75 | ALDH1A1 (0.64) | ALDH1A1GAACA1CA2ALOX12 | |
| SCHEMBL7690365 | 0.74 | GUSB (0.74) | ALDH1A1GAACA1CA2ALOX12 | |
| SCHEMBL10113658 | 0.74 | CA1 (0.77) | ALDH1A1CA1CA2ALOX12HTT | |
| SCHEMBL13419901 | 0.74 | ALDH1A1 (0.63) | ALDH1A1GAACA1CA2HTT | |
| SCHEMBL10112742 | 0.74 | ALDH1A1 (0.58) | ALDH1A1CA1CA2ALOX12HTT | |
| SCHEMBL10113582 | 0.73 | CA1 (0.67) | ALDH1A1CA1CA2ALOX12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | ALDH1A1 2125/4885GAA 98/4885CA1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.